| scholarly article | Q13442814 |
| P50 | author | Robert C G Martin | Q88780571 |
| Charles R. Scoggins | Q120516142 | ||
| P2093 | author name string | Vivek Sharma | |
| Tiffany Metzger | |||
| Dana Tomalty | |||
| Marshall Schreeder | |||
| Clifton Tatum | |||
| P2860 | cites work | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| Cancer statistics, 2002 | Q28216788 | ||
| Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale | Q33366660 | ||
| Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study | Q33622783 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe? | Q34602241 | ||
| Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi | Q34624438 | ||
| AHPBA/SSO/SSAT Consensus Conference on hepatic colorectal metastases: rationale and overview of the conference. January 25, 2006. | Q36585146 | ||
| A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer | Q36645980 | ||
| Transarterial Chemoembolization of Metastatic Colorectal Carcinoma with Drug-Eluting Beads, Irinotecan (DEBIRI): Multi-Institutional Registry | Q37407250 | ||
| Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report | Q37422471 | ||
| Cancer Statistics, 1977 | Q41222821 | ||
| The clinical correlation of an autopsy study of recurrent colorectal cancer | Q41603696 | ||
| Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry | Q42957008 | ||
| Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. | Q43882447 | ||
| Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment | Q44820379 | ||
| Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). | Q46990345 | ||
| Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. | Q52242528 | ||
| Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis | Q59901778 | ||
| Indicators of prognosis after hepatic resection for colorectal secondaries | Q67937217 | ||
| Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin | Q73330191 | ||
| Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal | Q73880478 | ||
| Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates | Q81712809 | ||
| Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study | Q84807162 | ||
| P433 | issue | 8 | |
| P921 | main subject | fluorouracil | Q238512 |
| pharmacokinetics | Q323936 | ||
| irinotecan | Q412197 | ||
| oxaliplatin | Q422327 | ||
| phase I clinical trial | Q5452194 | ||
| liver metastasis | Q18967325 | ||
| P304 | page(s) | 1531-1538 | |
| P577 | publication date | 2012-04-24 | |
| P1433 | published in | Journal of Gastrointestinal Surgery | Q15764393 |
| P1476 | title | Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial | |
| P478 | volume | 16 |
| Q37510082 | A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience |
| Q27022812 | A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof |
| Q34663557 | Colorectal hepatic metastasis: Evolving therapies |
| Q38353727 | Comparative effectiveness in hepatic malignancies |
| Q64941039 | Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer. |
| Q38691238 | DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. |
| Q41015601 | Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases |
| Q36518832 | Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model |
| Q48344683 | Hepatic Arterial Therapy for First-Line Treatment of Unresectable Colorectal Liver Metastases: What We Know in the Wake of Two Recent Randomized Control Trials. |
| Q52362144 | Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. |
| Q96166477 | Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study |
| Q30415022 | Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements |
| Q38072440 | Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement. |
| Q38206730 | Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review |
| Q38518842 | Minimal invasive treatments for liver malignancies |
| Q38398883 | Non-operative therapies for colorectal liver metastases |
| Q38813248 | Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial? |
| Q46463662 | Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. |
| Q38779462 | Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease |
| Q36498492 | Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series |
| Q51040976 | The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer. |
| Q38664762 | The state of regional therapy in the management of metastatic colorectal cancer to the liver |
| Q53573347 | Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. |
| Q95278037 | Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know |
| Q38531685 | Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review |
| Q91791481 | Updates of colorectal cancer liver metastases therapy: review on DEBIRI |
Search more.